Gogoro Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Gogoro Inc trades at $2.89 (market cap $56.21M), while Roivant Sciences Ltd. Common Shares trades at $35.26 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 439.8× Gogoro Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| GGR | ROIV | |
|---|---|---|
Market Cap | $56.21M | $24.72B |
Volume | 14,026 | 6,279,442 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $41.81 |
52-Week Low | $2.20 | $16.04 |
Typical Hold Time | 14 Days | 1 Days |
Enterprise Value | $342.65M | $20.99B |
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →